Trial highlights potential next-gen biologic for lung cancer
European Pharmaceutical Review
OCTOBER 25, 2024
The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings. The compound was designed to address issues such as payload toxicity seen in first-generation ADC therapies, according to Zai Lab.
Let's personalize your content